4.1.1.90	medicine	in WKY rats receiving a vitamin K-deficient diet that results in a 40% decrease of prothrombin activity, compound N-ethyl-2-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)tetradecylamide is able to counteract the effects on vitamin K deficiency and results in the complete restoration of prothrombin activity	747280	
4.1.1.90	medicine	multiplexed single nucleotide polymorphism panel (interrogation of the CYP2C9 *2, *3, VKORC1 (-1639G3A), and GGCX (1181T3G) alleles simultaneously) can be successfully used in genotyping of patient blood samples, whereby results can be combined with other clinical parameters in an algorithm for warfarin dosing	703270	
4.1.1.90	medicine	single nucleotide polymorphism in the GGCX gene may affect the dose of warfarin and other vitamin K antagonists	716953	
4.1.1.90	medicine	six out of seven patients with Pseudoxanthoma Elasticum habor mutations in the GGCX gene (gamma-glutamyl carboxylase)	699400	
4.1.1.90	medicine	warfarin therapy	699860	
4.1.1.90	synthesis	development of expression vectors which enable expressing mammalian gamma-glutamyl carboxylase, vitamin K epoxide reductase complex, subunit 1, and/or PDIA2 along with human coagulation factor VII in Drosophila Schnieder S2 cells. Mammalian GGCX i indispensable to synthesize active factor VII while mammalian vitamin K epoxide reductase complex, subunit 1, and PDIA2 are not critical but supportive factors for S2 cells	747630